ClinicalTrials.gg
RecruitingNCT07719556Updated Jul 22, 2026

Orelabrutinib Combined With Obinutuzumab and Short-Course Venetoclax in Patients With Treatment-Naïve Mantle Cell Lymphoma (MCL)

A Phase 2 interventional study of Orelabrutinib and Obinutuzumab in Mantle Cell Lymphoma (MCL), sponsored by The First Affiliated Hospital with Nanjing Medical University. Recruiting at 2 sites in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-07-22.

Sponsored by The First Affiliated Hospital with Nanjing Medical University · Phase 2, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
39
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 10 studies testing orelabrutinib in Lymphoma, Mantle-Cell — 8 open to participants now, 8 under way, 2 of them phase 3. orelabrutinib · Lymphoma, Mantle-Cell.

Planned enrollment
6th of 10
39 · median 42
Started
2026
the only one that year
Phase 2
5 of 10
5 open now
Registered
10th of 10
by date
Lead sponsor
1 of 10
The First Affiliated Hospital with Nanjing Medical University

Among the 10 studies testing orelabrutinib in Lymphoma, Mantle-Cell, this one is the 6th largest by planned enrollment, is the only one that started in 2026, is one of 5 in phase 2, and was the 10th registered.

Lymphoma, Mantle-Cell

1,223 studies on the registry are indexed under Lymphoma, Mantle-Cell; 156 are open to participants now.

Browse Lymphoma, Mantle-Cell studies →

Open to participants now

8 of the 10 studies testing orelabrutinib in Lymphoma, Mantle-Cell are open now, in 1 country. Recruiting first, the newest first:

2 more — sign in →

By country, each count listing its studies:

All 8 open studies →

Where they have run

About orelabrutinib

No approval found in the FDA or EMA files read. How studies give it is on its page →

Who these studies take

Of the 125 Lymphoma, Mantle-Cell studies recruiting now, 93 (74%) set no upper age limit and 12 (10%) stop at 75 or younger; 15 take children under 18; 2 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 10 studies testing orelabrutinib in Lymphoma, Mantle-Cell, or all of them as a file.
02

Study summary

This study aims to evaluate the safety and efficacy of orelabrutinib (O) in combination with obinutuzumab (G) and short-course venetoclax (V) in patients with treatment-naïve MCL.

Read the detailed description

MCL is difficult to cure, and the conventional treatment paradigm comprises a three-phase strategy: induction therapy based on intermediate- or high-dose cytarabine, consolidation with autologous stem cell transplantation (ASCT), and maintenance therapy with anti-CD20 monoclonal antibodies. Although this approach can yield long-term efficacy in young patients with MCL, it has notable limitations: it is less effective in patients with high-risk features such as a high Ki-67 index, TP53 mutations, or blastoid morphology, and elderly patients or those unfit for ASCT often cannot tolerate such intensive therapy.

Studies such as WINDOW-2 and BOVen have demonstrated that chemotherapy-free regimens combining a BTK inhibitor (BTKi), a BCL-2 inhibitor (BCL-2i), and an anti-CD20 monoclonal antibody are not limited by age and are equally effective in high-risk patients, making them a promising area of exploration for induction therapy in treatment-naïve MCL. However, the OASIS series of trials suggested that while the triplet regimen shows substantial efficacy and deeper responses in treatment-naïve MCL, it is also associated with a marked increase in adverse events (AEs). The safety concerns of triplet therapy should not be overlooked, and there is a need to explore novel therapeutic strategies that maintain efficacy while reducing the myelosuppression and treatment discontinuation rates associated with the addition of venetoclax.

This study aims to evaluate the safety and efficacy of orelabrutinib (O) in combination with obinutuzumab (G) and short-course venetoclax (V) in patients with treatment-naïve MCL. The induction phase consists of 6 cycles, in which venetoclax is introduced with dose ramp-up in Cycle 2 and subsequently administered for 14 days per cycle (thereby shortening the per-cycle exposure duration of venetoclax). This is followed by a maintenance phase in which orelabrutinib, obinutuzumab, and short-course venetoclax are continued up to Cycle 24. The primary endpoints are the complete response (CR) rate at the end of induction and the minimal residual disease (MRD) negativity rate assessed by immunoglobulin next-generation sequencing (IG-NGS) of plasma circulating tumor DNA (ctDNA). Secondary endpoints include safety, progression-free survival (PFS), overall survival (OS), and the correlation between ctDNA MRD dynamics and clinical outcomes.

03

Conditions studied

  • Mantle Cell Lymphoma (MCL)

Keywords

  • orelabrutinib
  • MCL
  • obinutuzumab
  • venetoclax
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Voluntarily participate and sign the form;
  2. Age ≥ 18 years, male or female;
  3. ≥ 3 months;
  4. (ECOG) performance status 0-2. Patients with ECOG 3 may be enrolled only if the decline in performance status is attributed to the underlying disease and the investigator determines that they may benefit from the treatment;
  5. confirmed diagnosis of mantle cell lymphoma (MCL) and treatment-naïve;
  6. Presence of measurable and/or evaluable lymphoma lesions;
  7. Adequate bone marrow reserve, defined as: > 1.0×10⁹/L or count > 75×10⁹/L, unless cytopenias are considered to be related to bone marrow involvement by lymphoma and deemed recoverable by the investigator;
  8. Hepatic function: (SGOT) and ALT (SGPT) ≤ 2.5 × (ULN) (in the absence of liver involvement) or ≤ 5 × ULN (in the presence of liver involvement); total (TBIL) ≤ ULN; serum creatinine (CRE) ≤ 1.5 × ULN;
  9. ≥ 30 mL/min, calculated using the Cockcroft-Gault formula;
  10. Able to comply with the study visit schedule and other protocol requirements;
  11. All patients of must agree to use effective measures during the study and for 24 months after study treatment discontinuation. Female patients of childbearing potential must have a negative urine pregnancy test prior to the first dose of study treatment.

Exclusion criteria

Exclusion Criteria:

  1. Received prior treatment for lymphoma within 2 weeks before study enrollment;
  2. Any serious medical condition, including but not limited to:

    • Uncontrolled hypertension (defined as blood pressure that remains uncontrolled after at least 4 weeks of treatment with a reasonable and tolerable regimen of 3 or more antihypertensive agents [including diuretics] at adequate doses, or requiring 4 or more antihypertensive agents to achieve adequate control);

      • Uncontrolled congestive heart failure within 6 months prior to screening ( [NYHA] Class III [moderate] or Class IV [severe] cardiac disease);

        • (LVEF) \< 50%;

          • Symptomatic coronary artery disease (e.g., chest tightness, chest pain, palpitations, fatigue) or coronary artery disease requiring medical therapy; ⑤Severe bradycardia (heart rate \< 40 beats per minute [bpm]) with hypotension, dizziness, or syncope; patients with a history of arrhythmia should undergo cardiac evaluation;

            • Known active bacterial, viral, fungal, or other infection (excluding fungal infection of the nail bed), or major infection within 2 weeks prior to the first dose of study drug;

              • Moderate to severe hepatic impairment ( Class B or C); ⑧Active bleeding within 2 months prior to screening, or clear evidence of bleeding diathesis as judged by the investigator; ⑨Current pulmonary disease that impairs lung function, such as pulmonary fibrosis or drug-related pneumonitis, which is deemed intolerable by the investigator; ⑩Any psychiatric or cognitive disorder that may limit the patient's ability to understand, execute, or comply with the and study requirements;
  3. Known active virus (HCV) infection; or other acquired or congenital immunodeficiency disorders, including but not limited to (HIV) infection;
  4. All patients with central nervous system (CNS) involvement by lymphoma;
  5. Diagnosis of or receiving treatment for another other than lymphoma, except for the following:

    ①Malignancy that has been treated with curative intent and with no known active disease for ≥ 5 years prior to enrollment;

    ②Adequately treated basal cell carcinoma of the skin (excluding melanoma) with no evidence of disease;

    ③Adequately treated carcinoma in situ of the cervix with no evidence of disease;

  6. Known to any study drug;
  7. Pregnant or breastfeeding women;
  8. History of stroke or intracranial hemorrhage within 6 months prior to enrollment;
  9. Requirement for anticoagulation therapy with warfarin or equivalent vitamin K antagonists;
  10. Requirement for long-term treatment with strong cytochrome P450 3A () inhibitors;
  11. Receipt of within 4 weeks prior to enrollment.
Terms in these criteria, in plain language(21)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

Child-Pugh class

A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
39 participants (estimated)

Study arms

  • Experimental
    orelabrutinib (O) combined with obinutuzumab (G) and short-course venetoclax (V)

    Induction Phase (6 cycles, 28 days per cycle): Orelabrutinib + Obinutuzumab \+ Venetoclax. Patients achieving partial response (PR) or complete response (CR) after 3 cycles will receive an additional 3 cycles of induction therapy.Patients with stable disease (SD) or progressive disease (PD) after 3 cycles will be withdrawn from the study.Patients achieving PR or CR at the end of induction will proceed to the maintenance phase (Cycles 7-24).Patients with SD or PD at the end of induction will be withdrawn from the study. Maintenance Phase (18 cycles, 28 days per cycle): Orelabrutinib + Obinutuzumab \+ Venetoclax

    Drug: Orelabrutinib · Drug: Obinutuzumab · Drug: Venetoclax

Interventions

  • Orelabrutinib: 150 mg, d1-d28, C1-C6 (Induction Phase ) ; 150 mg, d1-d28, C7-C24 (Maintenance Phase)

  • Obinutuzumab: 1000 mg/m², on d1, d8, and d15 in C1; and on d1 in C2-C6 (Induction Phase ) ; 1000 mg/m², d1, once every 2 cycles, C7-C24 (Maintenance Phase)

  • Venetoclax: dose ramp-up in C2 (20 mg → 400 mg); 400 mg on d1-d14 in C3-C6(Induction Phase ) ; 400 mg, d1-d14, C7-C24(Maintenance Phase)

06

What researchers measure

Primary outcomes

  1. Complete response rate (CRR)

    The CRR is defined as the proportion of patients who achieve a CR following therapy, calculated among all treated patients.

    Time frame: At the end of induction therapy (6 cycles, 28 days per cycle)

Secondary outcomes

  1. MRD negativity rate

    The MRD negativity rate is defined as the proportion of patients who achieve MRD negativity in peripheral blood following treatment, calculated among all treated patients.

    Time frame: At the end of induction therapy (6 cycles, 28 days per cycle)

  2. Objective response rate (ORR)

    The objective response rate (ORR) is defined as the proportion of patients who achieve a complete response (CR) or partial response (PR) after treatment, relative to the total treated population.

    Time frame: At the end of induction therapy (6 cycles, 28 days per cycle)

  3. 2-year progression-free survival (PFS)

    PFS is defined as the time from registration to the first occurrence of progression or relapse as assessed by the investigator, or death from any cause. PFS for patients without disease progression, relapse, or death will be censored at the time of the last tumor assessment.

    Time frame: From date of signing the informed consent until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 2 years

  4. Overall Survival (OS)

    Overall survival is defined as the period from the induction registration to death from any cause. Patients who have not died until the time of the analysis will be censored at their last contact date.

    Time frame: From date of signing the informed consent until the date of death from any cause, whichever came first (up to 3 years)

  5. The occurrence of adverse events and serious adverse events

    Adverse events will be graded by the investigator according to the NCI-CTCAE Version 5.0.

    Time frame: At the end of cycle 24 (28 days per cycle)

07

Study locations

2 of 2 sites recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Jul 2026; primary completion for Jul 2029, 35 months later.

Of 154 non-industry phase 2 interventional studies under Lymphoma, Mantle-Cell, half reached primary completion within 64 months of starting (the median), counting those still running; a quarter within 40 and three quarters within 108. This study's planned 35 months is below that.

Counting every sponsor, half of 184 studies reached it within 63 months; a quarter within 38 and three quarters within 106.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 17, 2026
First posted
Jul 22, 2026
StartEst.
Jul 15, 2026
Primary completionEst.
Jul 1, 2029
CompletionEst.
Jul 1, 2029
Last update
Jul 22, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 22, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT07719556
Responsible party
Sponsor
First posted
Jul 22, 2026
Start date
Jul 15, 2026 (estimated)
Primary completion
Jul 1, 2029 (estimated)
Completion
Jul 1, 2029 (estimated)
Last update
Jul 22, 2026

Study contacts

Yi Xia
Contact
cynthia0311@163.com
+8613770698391
Yi Xia
principal investigator · The First Affiliated Hospital with Nanjing Medical University

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Orelabrutinib

Start the discussion